A multimethylation reaction system of P2RX1, CBFA2T3, and CERS4 is used for early screening and diagnosis of pancreatic ductal adenocarcinoma.
By constructing a multiple methylation reaction system of P2RX1, CBFA2T3, and CERS4, the problem of poor specificity of CA19-9 detection was solved, enabling efficient screening and diagnosis of pancreatic ductal adenocarcinoma, reducing sample size and cost, and improving diagnostic efficiency.
Patent Information
- Application Number
- CN202311766617.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-20
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-12-20
AI Technical Summary
Existing technologies have poor specificity for CA19-9 detection, and methylation qPCR commonly uses fluorescent probe methods that require complex reaction systems, with high requirements for primer and probe design, making it difficult to achieve efficient early screening and diagnosis of pancreatic ductal adenocarcinoma.
Using at least one ctDNA methylation of P2RX1, CBFA2T3, and CERS4 as a biomarker, a multiple methylation reaction system was constructed for the screening and diagnosis of pancreatic ductal adenocarcinoma, including a multiple methylation reaction system of P2RX1 and CBFA2T3 and an independent CERS4 gene methylation reaction system.
The multiple QMSP response system reduced sample size, time and cost, and improved diagnostic efficacy. The combined diagnostic model showed significantly higher specificity and sensitivity than CA19-9 in screening for PDAC and assessing clinical staging.
Smart Images

Figure CN117987543B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, and in particular to a multimethylation reaction system of P2RX1, CBFA2T3 and CERS4 for early screening and diagnosis of pancreatic ductal adenocarcinoma. Background Technology
[0002] Pancreatic cancer (PC) is a common malignant tumor of the digestive system. Most pancreatic cancers are characterized as pancreatic ductal adenocarcinoma (PDAC), accounting for more than 90% of pancreatic exocrine malignancies. In 2021, pancreatic cancer ranked fourth in incidence among all malignant tumors, with a 5-year survival rate of only 10% at diagnosis. It is projected to become the second leading cause of cancer death within the next 20 to 30 years.
[0003] Most pancreatic cancer patients are diagnosed at an advanced stage due to the highly aggressive nature of the tumor and the lack of typical early symptoms; only 10-20% of patients are eligible for surgical treatment. Traditionally, the gold standard for diagnosing pancreatic tumors is the use of tissue samples from surgical or biopsy specimens. Because the pancreas is a retroperitoneal organ, tissue can only be obtained through surgery or endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA), and these procedures cannot be repeated. Routine examinations also fail to reflect changes in tumor dynamics and drug sensitivity as the disease progresses.
[0004] Therefore, early detection of cancerous changes is the key to the prevention and treatment of pancreatic cancer. Currently, serum CA19-9 is the only biomarker approved by the FDA for the diagnosis and monitoring of pancreatic cancer.
[0005] For pancreatic cancer patients with abnormal CA19-9 levels, CA19-9 is associated with tumor stage or burden, and therefore can be used to predict prognosis and surgical assessment. However, its specificity is poor, and it is not recommended for early screening of PDAC. Therefore, new methods for PDAC screening and early diagnosis need to be developed.
[0006] Currently, the most commonly used method for methylation qPCR (QMSP) is the fluorescent probe method. Because it requires amplification of DNA converted by bisulfite, the reaction system is different from that of ordinary qPCR, and the design requirements for primers and probes are also higher. Summary of the Invention
[0007] The purpose of this invention is to address the technical problem that the CA19-9 detection specificity in the prior art is poor, while the commonly used methylation qPCR (QMSP) method is the fluorescent probe method. Since it is necessary to amplify DNA converted by bisulfite, the reaction system is different from that of ordinary qPCR, and the design requirements of primers and probes are also higher.
[0008] To achieve the above objectives, the present invention adopts the following technical solution:
[0009] Application of ctDNA methylation of at least one of CBFA2T3, P2RX1 and CERS4 as a biomarker in the preparation of products for early screening and diagnosis of pancreatic ductal adenocarcinoma.
[0010] Preferably, the product includes a multiple methylation reaction system constructed by methylating two of P2RX1, CBFA2T3 and CERS4 ctDNA.
[0011] Preferably, the product includes a multiple methylation reaction system constructed from P2RX1 and CBFA2T3 and an independent CERS4 gene methylation reaction system.
[0012] This application also provides a product for screening and diagnosing pancreatic ductal adenocarcinoma, the product comprising a multimethylation reaction system.
[0013] Preferably, the multiple methylation reaction system is constructed using DNA methylation in the 5'UTR region of the P2RX1 and CBFA2T3 genes in plasma as biomarkers.
[0014] Compared with the prior art, this application has the following advantages:
[0015] 1. In this application, by constructing a multiple QMSP reaction system, the sample size, time and cost are reduced compared with a single system, and the diagnostic efficacy is improved.
[0016] 2. Secondly, the combined diagnostic model has significantly higher specificity and sensitivity than CA19-9 and single models in screening for PDAC and assessing clinical staging. Attached Figure Description
[0017] Figure 1 This is a flowchart illustrating the technical route for screening differentially methylated genes (DMGs) in one embodiment of the present invention.
[0018] Figure 2 This is a heatmap and functional enrichment analysis of differentially methylated genes in one embodiment of the present invention. (The image shows...)
[0019] (b, c) Red circles represent P2RX1 enriched entries, green circles represent CBFA2T3, and blue arrows represent CERS4;
[0020] Figure 3 This is a gene DMR locus screened using multiple QMSP validation in one embodiment of the present invention. (a) shows the triple QMSP amplification curve of tissue DNA using a Roche 96 instrument, FAM: P2RX1, HEX:
[0021] β-actin, CY5:CBFA2T3. (b, c) Relative methylation levels of P2RX1 and CBFA2T3 genes in 15 cases of pancreatic ductal adenocarcinoma and adjacent normal tissues. (d) Images of plasma DNA multiplex amplification curves. (e, f)
[0022] The relative methylation levels of P2RX1 and CBFA2T3 genes in the plasma of 30 normal individuals undergoing physical examinations and 60 individuals with PDAC.
[0023] Figure 4 This is a multi-factor diagnostic performance analysis of PDAC in one embodiment of the present invention. Wherein (a, b)
[0024] The relative methylation levels of P2RX1 and CBFA2T3 tumor stages compared to normal controls differed. (c)
[0025] Differences in CA19-9 tumor staging compared to normal controls. (d, e) Receiver operating curve (ROC) analysis of multivariate model for diagnosing PDAC. Detailed Implementation
[0026] The present invention will be further described in detail below with reference to specific embodiments.
[0027] Application of ctDNA methylation of at least one of CBFA2T3, P2RX1 and CERS4 as a biomarker in the preparation of products for early screening and diagnosis of pancreatic ductal adenocarcinoma.
[0028] Specifically, in one embodiment, the product includes a multiple methylation reaction system constructed by methylating any two of P2RX1, CBFA2T3, and CERS4 ctDNA.
[0029] Preferably, the product includes a multiple methylation reaction system constructed from P2RX1 and CBFA2T3 and an independent CERS4 gene methylation reaction system.
[0030] This application also provides a product for screening and diagnosing pancreatic ductal adenocarcinoma, the product comprising a multimethylation reaction system.
[0031] In one embodiment, the multiple methylation reaction system is constructed using DNA methylation in the 5'UTR region of the P2RX1 and CBFA2T3 genes in plasma as biomarkers.
[0032] The above content will be described below with reference to specific embodiments:
[0033] Example 1: Gene Screening
[0034] Please see Figure 1 and Figure 2In this application, whole-genome bisulfite methylation sequencing (WGBS) was used to identify 112,294 DMRs based on at least 5 methylation sites (CpG) in each differentially methylated region (DMR).
[0035] Focusing on the promoter regions of hypermethylated genes in tumors (|Difference|>0.15, P<0.05), 4709 genes were obtained.
[0036] Simultaneously, RNA-seq data of PDAC tissues were downloaded from the GEO database, and 1783 genes with low expression in PDAC tissues were identified based on logFC < -0.5 and P < 0.05. Intersection with hypermethylated genes in the promoter region yielded 153 genes.
[0037] Further analysis using the GEPIA database identified eight genes with high methylation and low expression: TDH, PLIN4, PLIN5, CBFA2T3, CERS4, P2RX1, FKBP11, and SLC7A2.
[0038] Functional enrichment analysis was performed on the genes involved based on the distribution of DMRs in the genome and their overlap with promoter regions (from 1.5 Kb upstream to 0.5 Kb downstream of the transcription start site). Among the first 15 KEGG and GO analysis entries, only CBFA2T3, CERS4, and P2RX1 were enriched. Figure 2 (b, c).
[0039] Predictions based on public databases showed that the expression of three genes in PDAC tissue was higher than in normal pancreatic tissue and was associated with poor prognosis. Figure 2 .df).
[0040] Example 2: Validation of methylation levels of CBFA2T3, CERS4, and P2RX1
[0041] Based on previously identified differentially methylated sites, the region containing these sites was determined for verification; this DNA fragment is the target fragment. Therefore, QMSP primers and probes were designed using this sequence as a template to verify the difference in methylation levels between the case group and the control group in this region. Primer design was performed using the online software methprimer 1.0, and probes were designed using BeaconDesigner.
[0042] Using actin β-actin (ACTβ) as an internal reference gene, primers and probes were designed from a CpG-free region to avoid false negatives. Fully methylated male human brain tissue DNA treated with M.SssI methyltransferase was used as a positive control to generate a standard curve for quantification.
[0043] Primers and probes were synthesized by Shanghai Sangon Biotech Co., Ltd., and their sequences are shown in Table 1.
[0044] Table 1 Primer and probe sequences for P2RX1, CBFA2T3, and CERS4 multiple methylation PCR
[0045]
[0046] The total QMSP reaction volume was 20 μL, including 0.4 μL each of 10 μmol / L forward and reverse primers, 0.2 μL of 10 μmol / L probe, 2 μL of BS-DNA, 10 μL of AceQ qPCR ProbeMaster Mix (Vazyme, Q112), and 5 μL of ddH2O. The cycling parameters were: 95℃ for 10 min; 95℃ for 15 s, 58℃ for 1 min, for a total of 55 cycles. Fluorescence signals were collected using a 96-instrument at 58°C. Each sample was tested in triplicate; samples that failed to amplify a curve in two tests were considered invalid. For each gene, the relative methylation level (percent of methylated reference) PMR for each sample was calculated as 2 - ΔΔCt × 100%. ΔΔCt = [Ct(Gene) - Ct(ACTβ)](Sample) - [Ct(Gene) - Ct(ACTβ)](M.SssI treated normal DNA).
[0047] Considering that ctDNA is broken down from tumor cells in tissues and enters the bloodstream, we first established a stable multiplex QMSP system in 15 pairs of patient tissues, and selected the P2RX1 (P<0.05) and CBFA2T3 (P<0.01) combination with differences in methylation between groups. Figure 3 .ac). Next, multiple QMSP validation was performed on plasma ctDNA from 60 PDAC patients: compared to the methylation levels of P2RX1 and CBFA2T3 in normal plasma, these two genes were significantly hypermethylated in PDAC, with statistically significant differences. Figure 3 .df).
[0048] Further analysis of the relationship between clinical stage and methylation revealed that P2RX1 methylation levels in stage IIA and III tumors were significantly higher than in normal individuals, with statistically significant differences. Similarly, CBFA2T3 methylation levels in stage IB, IA, IIB, and III tumors were significantly higher than in normal individuals, with statistically significant differences. Figure 4 a, b). CERS4 failed to be integrated into the multi-level (P2RX1 / CBFA2T3) system, and was verified using the single-level QMSP method.
[0049] like( Figure 4Figures d and e show the receiver operating characteristic (AUC) curves of a multivariate model for three differentially methylated genes (DMGs): P2RX1, CBFA2T3, and CERS4, and the positive control CA19-9. It can be seen that CERS4's AUC for diagnosis alone is superior to CA19-9, but its sensitivity is lower, while its specificity is equal to CA19-9. In the P2RX1 and CBFA2T3 multivariate model, we integrated both genes using logistic regression, and their combined diagnostic efficacy was significantly better than CA19-9, with higher AUC, sensitivity, and specificity. To further improve diagnostic efficacy, we sequentially integrated all three genes to construct a gene model, which showed even higher diagnostic efficacy.
[0050] This application, through WGBS sequencing, identified the potential biomarkers P2RX1, CBFA2T3, and CERS4 for PDAC for the first time, and established a stable multiplex QMSP reaction system (P2RX1 and CBFA2T3) in plasma. The method demonstrated high specificity and reproducibility in the quantitative detection of methylated and unmethylated alleles. The methylation levels of CBFA2T3 and P2RX1 in the plasma of PDAC patients were significantly higher than those in normal individuals, with statistically significant differences. Compared to a single QMSP system that independently analyzes two methylated genes, the multiplex QMSP system in this study allows for repeated analysis of up to 30 samples in a 96-well plate format for each assay. Only one standard curve is needed to quantify the three genes, which significantly reduces the consumption of CpGenome™ universal methylated DNA and template DNA, lowering costs and improving detection efficiency. Especially in in vitro detection, the limited DNA extracted from body fluids is more suitable for multiplex reactions.
[0051] Furthermore, the methylation levels of CBFA2T3 and P2RX1 in the plasma of PDAC patients were significantly higher than those in normal individuals, with statistically significant differences. Moreover, these two genes showed significant differences in tumor stages IIA and III, superior to CA19-9. Combined with the independent CERS4 gene, the three-gene combined diagnostic model can be used for screening and assessing the clinical stage of PDAC.
[0052] This application, through WGBS sequencing, identified for the first time the potential biomarkers P2RX1, CBFA2T3, and CERS4 for PDAC, and established a stable multiplex QMSP reaction system (P2RX1 and CBFA2T3) in plasma. The method demonstrated high specificity and reproducibility in the quantitative detection of methylated and unmethylated alleles. The methylation levels of CBFA2T3 and P2RX1 in the plasma of PDAC patients were significantly higher than those in normal individuals, with statistically significant differences. Compared to a single QMSP system that independently analyzes two methylated genes, the multiplex QMSP system in this study allows for repeated analysis of up to 30 samples in a 96-well plate format for each assay. Only one standard curve is needed to quantify all three genes, which significantly reduces the consumption of CpGenome™ universal methylated DNA and template DNA, lowering costs and improving detection efficiency. Especially in in vitro detection, the limited DNA extracted from body fluids is more suitable for multiplex reactions.
[0053] Secondly, the methylation levels of plasma CBFA2T3 and P2RX1 in PDAC patients were significantly higher than those in normal individuals, with statistically significant differences. Furthermore, these two genes showed significant differences in tumor stages IIA and III, superior to CA19-9. Combined with the independent CERS4 gene, this three-gene diagnostic model can be used for screening and assessing the clinical stage of PDAC.
[0054] In summary, the application of at least one of CBFA2T3, P2RX1, and CERS4 as biomarkers in the preparation of products for early screening and diagnosis of pancreatic ductal adenocarcinoma (PDAC) using a multiplex QMSP reaction system reduces sample size, time, and cost compared to a single system, while improving diagnostic efficacy. The combined diagnostic model demonstrates significantly higher specificity and sensitivity than CA19-9 in screening and assessing clinical staging of PDAC.
Claims
1. Use of a reagent for detecting at least one ctDNA methylation biomarker in CBFA2T3, P2RX1 and CERS4 in the manufacture of a product for early screening and diagnosis of pancreatic ductal adenocarcinoma, characterized in that: The reagents are primers and probes for detecting biomarkers CBFA2T3, P2RX1, and CERS4, as shown below: 。 2. The application of the reagent for detecting at least one ctDNA methylation biomarker among CBFA2T3, P2RX1, and CERS4 according to claim 1 in the preparation of products for early screening and diagnosis of pancreatic ductal adenocarcinoma, characterized in that: The product includes a multiple methylation reaction system constructed from P2RX1 and CBFA2T3 and an independent CERS4 gene methylation reaction system.
3. A product for screening and diagnosing pancreatic ductal adenocarcinoma, characterized in that: The product includes a multiple methylation reaction system, which includes the primers and probes for detecting the biomarkers CBFA2T3 and P2RX1 as described in claim 1; the multiple methylation reaction system is constructed using DNA methylation in the 5'UTR region of the P2RX1 and CBFA2T3 genes in plasma as biomarkers.
Citation Information
Patent Citations
Marker for examining pancreatic ductal adenocarcinoma by using methylation level of locus CpG and application of marker
CN112176057A
DNA methylation marker of pancreatic ductal adenocarcinoma and application of DNA methylation marker
CN114250298A
